During the recent session, Virpax Pharmaceuticals Inc (NASDAQ:VRPX)’s traded shares were 0.81 million, with the beta value of the company hitting 1.01. The 52-week high for the VRPX share is $5.48, that puts it down -2784.21 from that peak though still a striking 5.26% gain since the share price plummeted to a 52-week low of $0.18. The company’s market capitalization is $4.96M, and the average trade volume was 5.60 million shares over the past three months.
Virpax Pharmaceuticals Inc (NASDAQ:VRPX) trade information
Virpax Pharmaceuticals Inc (VRPX) registered a -3.61% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.61% in intraday trading to $0.19, hitting a weekly high. The stock’s 5-day price performance is -17.69%, and it has moved by -35.07% in 30 days. Based on these gigs, the overall price performance for the year is -95.03%.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 93.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, VRPX is trading at a discount of -1478.95% off the target high and -1478.95% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 14.86%. While earnings are projected to return 78.10% in 2025, the next five years will return 66.22% per annum.
VRPX Dividends
Virpax Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Virpax Pharmaceuticals Inc (NASDAQ:VRPX)’s Major holders
Also, the Mutual Funds coming in first place with the largest holdings of Virpax Pharmaceuticals Inc (VRPX) shares are Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 25.31 shares. This amounts to just over 0.17 percent of the company’s overall shares, with a $4737.0 market value. The same data shows that the other fund manager holds slightly less at 8.76, or about 0.06% of the stock, which is worth about $1639.0.
